EFFECTS OF DERMATAN SULFATE, A HEPARIN-COFACTOR-II MEDIATED THROMBIN INHIBITOR, ON THE ENDOTOXIN-INDUCED DISSEMINATED INTRAVASCULAR COAGULATION MODEL IN THE RAT - COMPARISON WITH LOW-MOLECULAR-WEIGHT HEPARIN, NAFAMOSTAT MESILATE AND ARGATHROBAN

Effects of dermatan sulfate (DS) on the endotoxin-induced disseminated intravascular coagulation (DIC) rat model were compared with those of low-molecular weight heparin (LMWH), nafamostat mesilate (NM) and arg athroban (AR). At doses of 5, 10 or 20 mg/kg/4 hr, DS significantly am eliorated the decrease of fibrinogen (Fbg), the increase of fibrin-fib rinogen degradation products (FDP) and except at the highest dose (20 mg/kg/4 hr), the prolongation of thrombin clotting time (TCT). It also decreased the glomerular fibrin deposits (%GFD) at doses of 10 or 20 mg/kg/4 hr. LMWH suppressed the decrease of Fbg and the increase of FD P at doses of 1.4 or 2.8 mg/kg/4 hr. Only the highest dose of LMWH sup pressed the decrease of the platelet count (PL), the prolongation of p rothrombin time, and improved the %GFD. AR suppressed the decrease of PL and improved the %GFD. At the dose required to improve the %GFD, DS (5, 10 mg/kg/4 hr) significantly suppressed the prolongation of TCT, which is related to the bleeding frequency, while LMWH and AR further increased the prolongation of the TCT. These results suggest that DS h as potential as a therapeutic drug with a lower hemorrhagic risk as co mpared with LMWH and AR in the treatment of DIC.